Hospital

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

Results of the analysis may help inform future COVID-19 vaccine development, investigators say.

The FDA has approved Difelikefalin injection (Korsuva; Cara Therapeutics and Vifor Pharma) for the treatment of moderate-to-severe chronic kidney disease–associated pruritus in adults undergoing hemodialysis.

Ten quiz questions to assess your knowledge on common symptoms and treatments for Hodgkin's lymphoma.

The approval is based on the results of the ACTIVATE and ACTIVATE-T phase 3 studies, Agios Pharmaceuticals says.

Women who get these screenings starting at aged 30 to 35 years could cut their cancer mortality by more than 50%, new study results show.

During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.

At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.

Hospital-onset clostridium difficile infections frequently occur because of both patient and environmental risk factors.

The treatment for hypertrophic cardiomyopathy met its primary endpoint at week 6 in the phase 3 VALOR-HCM trial, the pharmaceutical company says.

Finerenone (Kerendia) is indicated to reduce the risk of sustained eGFR decline, end stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease.

The application is based on data showing that lisocabtagene provides clinically meaningful and statistically significant improvement for those with relapsed or refractory large B-cell lymphoma.

In the report published by The Lancet, the group provides a brief history of drug use and addiction, describes the opioid landscape, and includes 7 recommendations.

Sachin Nagrani, MD, the medical director of Heal, discusses his predictions for the future as we continue to fight the COVID-19 pandemic.

Although prevention decreased with time, a third booster dose was still highly effective at preventing severe illness with COVID-19.

Data from the CALIBRATE and CAPELLA trials show high rates of virologic suppression with the capsid inhibitor.

The drug combination reduced the risk of disease progression by 34% versus the standard of care in first-line metastatic castration-resistant prostate cancer, clinical trial results show.

The variants include Alpha, Beta, Gamma, Delta, and Omicron, and the laboratory results are consistent with other analyses.

The best start for improving medication adherence in the pharmacy is initiating the conversations with patients that are necessary for their health.

Cohort H of the phase 1b/2 EV-103 trial enrolled patients with MIBC who were eligible for surgical treatment but ineligible for cisplatin-based chemotherapy.

Rachel Rubin, MD, an assistant clinical professor in urology at Georgetown University and a urologic surgeon, discusses some of the common practices for the treatment of hypoactive sexual desire disorder in women and men.

Sachin Nagrani, MD, the medical director of Heal, discusses what pharmacists should know about the Omicron variant and other variants popping up globally.

The investigators identified this in 9% of relapsed cases of pediatric acute myeloid leukemia, but it also was present in primary samples.

Dalpiciclib added to fulvestrant (Faslodex) was found to significantly prolong progression-free survival compared with fulvestrant monotherapy in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative advanced breast cancer.

The safety of an anti-coronavirus hyperimmune intravenous immunoglobulin may be influenced by whether an individual is able to naturally generate SARS-CoV-2-neutralizing antibodies.

Just 2 of 41 nutritionists interviewed reported using a validated screener, while 4 others said they use other tools, such as screening questions developed by other organizations, results show.

The continued upward trend in testing and vaccination demand, coupled with staffing shortages, technology gaps, and never-ending to-do lists, exacerbates spikes in patient volume and workload for pharmacy professionals.

FDA to evaluate adagrasib for the treatment of patients with non–small cell lung cancer with tumors that have a KRAS G12C mutation.

Through the 240 weeks, numerically small median changes in eGFR and stable TC:HDL ratios were observed in both studies.